Ed Silverman

Ed Silverman has covered the pharmaceutical industry for more than three decades, focusing on pricing, affordability and access, regulation, marketing, and the legal battles surrounding major drug companies. Silverman’s reporting on prescription drug pricing led to him being named a Pulitzer Prize finalist in explanatory journalism.

Articles by Ed Silverman

Inside Pharma's Patent Battleground: The Policy Changes Reshaping Generic and Biosimilar Competition

ByEd Silverman

August 4th 2026

Recent changes at the U.S. Patent and Trademark Office are making it harder to challenge pharmaceutical patents, raising concerns that slower generic and biosimilar competition could undermine efforts to lower drug costs while strengthening protections for brand-name innovators.

Ed Silverman

Articles by Ed Silverman

Inside Pharma's Patent Battleground: The Policy Changes Reshaping Generic and Biosimilar Competition

Latest Updated Articles

Trending on PharmExec

Pharmaceutical Executive Daily: AstraZeneca and Bristol Myers Squibb Held Merger Talks

AstraZeneca and Bristol Myers Squibb Held Merger Talks: Report

Sandoz Agrees to $450 Million Settlement With 43 US States Over Generic Drug Antitrust Claims

Addressing China’s Rise in Biotech by Removing Barriers: Q&A with John Stanford

Why Biologics R&D Platforms Are Failing Complex Modalities and What Must Change